Genome-wide association study identifies polymorphisms associated with the analgesic effect of fentanyl in the preoperative cold pressor-induced pain test. by Takahashi, K et al.
Posted at the Institutional Resources for Unique Collection and Academic Archives at Tokyo Dental College,
Available from http://ir.tdc.ac.jp/
Title
Genome-wide association study identifies
polymorphisms associated with the analgesic effect




Takahashi, K; Nishizawa, D; Kasai, S; Koukita, Y;
Fukuda, KI; Ichinohe, T; Ikeda, K
Journal




This is an open access article distributed under
the terms of the Creative Commons CC BY license,
which permits unrestricted use, distribution, and
reproduction in any medium, provided the original
work is properly cited.
Description
Full paper
Genome-wide association study identifies polymorphisms
associated with the analgesic effect of fentanyl in the preoperative
cold pressor-induced pain test
Kaori Takahashi a, b, 1, Daisuke Nishizawa b, 1, Shinya Kasai b, Yoshihiko Koukita a,
Ken-ichi Fukuda c, Tatsuya Ichinohe a, Kazutaka Ikeda b, *
a Department of Dental Anesthesiology, Tokyo Dental College, 2-9-18 Misaki-cho, Chiyoda-ku, Tokyo 101-0061, Japan
b Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan
c Division of Special Needs Dentistry and Orofacial Pain, Department of Oral Health and Clinical Science, Tokyo Dental College, 2-9-18 Misaki-cho,
Chiyoda-ku, Tokyo 101-0061, Japan
a r t i c l e i n f o
Article history:
Received 26 September 2017
Received in revised form
7 November 2017
Accepted 10 November 2017







a b s t r a c t
Opioid analgesics are widely used for the treatment of moderate to severe pain. The analgesic effects of
opioids are well known to vary among individuals. The present study focused on the genetic factors that
are associated with interindividual differences in pain and opioid sensitivity. We conducted a multistage
genome-wide association study in subjects who were scheduled to undergo mandibular sagittal split
ramus osteotomy and were not medicated until they received fentanyl for the induction of anesthesia.
We preoperatively conducted the cold pressor-induced pain test before and after fentanyl administration.
The rs13093031 and rs12633508 single-nucleotide polymorphisms (SNPs) near the LOC728432 gene
region and rs6961071 SNP in the tcag7.1213 gene region were significantly associated with the analgesic
effect of fentanyl, based on differences in pain perception latency before and after fentanyl adminis-
tration. The associations of these three SNPs that were identified in our exploratory study have not been
previously reported. The two polymorphic loci (rs13093031 and rs12633508) were shown to be in strong
linkage disequilibrium. Subjects with the G/G genotype of the rs13093031 and rs6961071 SNPs presented
lower fentanyl-induced analgesia. Our findings provide a basis for investigating genetics-based analgesic
sensitivity and personalized pain control.
© 2018 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
1. Introduction
Clinicians often need to consider patients' interindividual differ-
ences in pain and the effects of analgesics. Individual differencesmay
be related to various environmental factors, mental factors, and ge-
netic factors. Several studies have reported associations between
pain sensitivity and polymorphisms of the genes that encode cate-
chol-O-methyltransferase (COMT),1,2 opioid receptor m 1 (OPRM1),3,4
and GTP cyclohydrolase 1 (GCH1),5,6 among others. Genetic factors
reportedly contribute to the differential response to opioids by
possibly regulating their pharmacokinetics (metabolizing enzymes
and transporters) and pharmacodynamics (receptors and signal
transduction).7 Indeed, genetic polymorphisms of the cyclic adeno-
sine monophophosphate response element binding protein 1
(CREB1), calcium voltage-gated channel subunit a1E (CACNA1E),
dopamine receptor D4 (DRD4), adrenoceptor b1 (ADRB1), OPRM1,
and adenosine triphosphate binding cassette subfamily B member 1
(ABCB1) genes have been reported to influence the analgesic effects
of opioids.8e12
Studies that seek to replicate previously reported genetic poly-
morphisms often report inconsistent or even opposite outcomes
because of variable study designs, sample heterogeneity, small
sample sizes, phenotype complexity, and the use of different sta-
tistical approaches.13 More research is needed to reveal the basis of
interindividual differences in pain and analgesic sensitivity. Thanks
to recent advances in genome science, large-scale genotyping has
been established, and this technological advancement simplified
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the analysis of genetic factors. More than one million single-
nucleotide polymorphisms (SNPs) throughout the genome can be
comprehensively analyzed by conducting genome-wide associa-
tion studies (GWASs). GWASs and other association studies will
likely contribute to personalized medical care and pain control, in
which opioid sensitivity and the side effects of opioids (e.g., fen-
tanyl) can be predicted based on genetic polymorphisms.14
Previous studies that investigated interindividual differences in
analgesic sensitivity tended to include subjects who were already
in a state of pain (e.g., cancer pain and postoperative pain) when
theywere treated with analgesic medications. The inclusion of such
subjects can cause difficulty in selecting subjects who are in exactly
the same condition when evaluating individual differences in drug
sensitivity. Patients who are scheduled to undergo mandibular
sagittal split ramus osteotomy (SSRO)15,16 are considered ideal
because they do not have pain before surgery. Furthermore, many
of them are young, and they are currently unmedicated when they
receive fentanyl for the induction of anesthesia. This makes them
nearly ideal subjects for examining preoperative pain sensitivity
and analgesic effects. Our previous study evaluated the analgesic
effect of fentanyl in the preoperative cold pressor-induced pain test.
Analgesia was defined as the difference in pain sensitivity before
and after fentanyl administration (PPLpostePPLpre).17 We identi-
fied SNPs that were associated with the analgesic effects of fentanyl
in the cold pressor-induced pain test.17e19
Previous studies have not performed GWAS to comprehensively
investigate genetic polymorphisms that are associated with pain
sensitivity (PPLpre) and the analgesic effects of fentanyl in that
evaluation (PPLpost-PPLpre). Therefore, the present study investi-
gated genetic polymorphisms that are associated with PPLpre and
PPLpostePPLpre in subjects who were scheduled to undergo SSRO
by performing a GWAS. We found several SNPs that were genome-
wide significantly associated with the analgesic effects of fentanyl.
2. Materials and methods
2.1. Ethics statement
The study protocol was approved by the Institutional Review
Boards at Tokyo Dental College (Tokyo, Japan) (Approval No. 86),
and Tokyo Metropolitan Institute of Medical Science (Tokyo, Japan)
(Approval No. 15-6). All of the subjects provided informed, written
consent for the genetics studies.
2.2. Subjects
Enrolled in this GWAS were 355 healthy patients (American
Society of Anesthesiologists Physical Status I, age 15e52 years, 125
males and 230 females) who were scheduled to undergo SSRO for
mandibular prognathism at Tokyo Dental College Suidobashi Hos-
pital. The detailed demographic and clinical data of the subjects
were reported in a previous study.11
2.3. Preoperative cold pressor-induced pain test
All the patients were premedicated with oral diazepam, 5 mg,
and oral famotidine, 150 mg, 90 min before the induction of anes-
thesia. The temperature in the operating room was maintained at
26 C. The cold pressor-induced pain test was then performed
before and 3 min after an intravenous (i.v.) bolus injection of fen-
tanyl, 2 mg/kg, as previously described.20,21 Briefly, crushed ice
cubes and cold water were blended 15 min before testing in a 1-L
isolated tank, and the mixture was stirred immediately before
each test to ensure the uniform distribution of temperature (0 C)
within the tank. The dominant hand was immersed up to the wrist.
The patients were instructed to keep their hand calm in the ice-cold
water and withdraw it as soon as they perceived any pain. The
baseline latency to pain perception, defined as the time of im-
mersion of the hand in the ice water, before the i.v. injection of
fentanyl (PPLpre) was recorded. A cut-off point was set at 150 s. The
hand was warmed with a hair dryer as soon as it was withdrawn
from the ice water until the sensation of cold was completely
abolished. We then injected i.v. fentanyl, 2 mg/kg. Three minutes
after the injection, the pain perception latency of the dominant
hand (PPLpost) was measured again. The analgesic effect of fenta-
nyl in the preoperative cold pressor-induced pain test was evalu-
ated simply as the difference between PPLpost and PPLpre
(PPLpostePPLpre).
2.4. Genotyping procedure and linkage disequilibrium analysis
Genomic DNA was extracted from whole-blood samples as
described previously.11 The DNA concentration was adjusted to
5e50 ng/ml for genotyping an individual SNP or 100 ng/ml for
whole-genome genotyping. The procedure for whole-genome
genotyping was fundamentally the same as in a previous study.11
Briefly, whole-genome genotyping was performed using the
Infinium assay II and an iScan system (Illumina, San Diego, CA, USA)
according to the manufacturer's instructions. Five kinds of Bead-
Chips were used to genotype the samples. Approximately 300,000
SNP markers were commonly included in all of the BeadChips, and
these markers were considered for our association analyses. After
whole-genome genotyping, the data for genotyped samples were
analyzed using BeadStudio or GenomeStudio with Genotyping
module v3.3.7 (Illumina) to evaluate the quality of the results as
described previously.4
To secondarily analyze SNPs within and around the LOC728432
gene region, which includes the most potent SNPs that were
selected after the GWAS, genotype data that resulted from whole-
genome genotyping as described previously1 were basically used.
To identify the relationships between the SNPs located in the
LOC728432 gene region, linkage disequilibrium (LD) analysis was
performed for the SNPs with a minor allele frequency  0.05 in the
genomic position ranging from 87,915,041 to 89,987,572 using
Haploview v. 4.2222 based on the genotype data for 127 of 355
subjects. For the estimation of LD strength between the SNPs, the
commonly used r2 values were pairwise-calculated using the ge-
notype dataset of each SNP. Linkage disequilibrium blocks were
defined among the SNPs that showed “strong LD,” based on the
default algorithm of Gabriel et al.,23 in which the upper and lower
95% confidence limits on D0 for a strong LD were set to 0.98 and 0.7,
respectively.
2.5. Genome-wide association study
A multistage GWAS was conducted for the patients who un-
derwent painful cosmetic surgery to investigate the association
between genetic variations and pain and the analgesic effect of
fentanyl. Among the 355 subjects, one subject lacked preoperative
clinical data, and another subject did not meet the criteria for
quality control in our preliminary analysis. Therefore, a total of 353
subjects were used for our multistage GWAS (118, 117, and 118
subjects for the first-, second-, and final-stage analyses, respec-
tively). The average agewas 26.0 years (28males and 90 females) in
the first-stage analysis, 25.5 years (51 males and 66 females) in the
second-stage analysis, and 26.2 years (46 males and 72 females) in
the final-stage analysis. In our preliminary analysis that used
merged markers between different BeadChips with BeadStudio or
GenomeStudio, 295,036 SNPs were selected for the analyses.
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Before the analyses, the quantitative values of PPLpostePPLpre
(s) were natural-log-transformed for approximation to the
normal distribution according to the following formula in the
case of zero or positive values: Value for analyses ¼ Ln
(1 þ PPLpostePPLpre [s; log-transformed]). In the case of negative
values, we used the following formula: Value for analyses¼ -Ln (1 -
PPLpostePPLpre [s; log-transformed]). To explore the association
between the SNPs and phenotype, linear regression analyses were
conducted in each stage of the analysis, in which PPLpre or
PPLpostePPLpre (s) and the genotype data for each SNP were
incorporated as dependent and independent variables, respec-
tively. Additive, dominant, and recessive genetic models were used
for the analyses. The male genotypes were excluded from the
analysis of X chromosome markers. All of the statistical analyses
were performed using gPLINK v. 2.050, PLINK v. 1.07 (http://pngu.
mgh.harvard.edu/purcell/plink/; accessed September 24, 2017),24
and Haploview v. 4.1.22
The GWAS procedure is summarized in a previous study.11 In the
first- and second-stage analyses, the SNPs that showed statistical P-
values less than 0.05 were selected as the candidate SNPs for the
next stage analysis. In the final stage, the Q-values of the false
discovery rate were calculated to correct for multiple testing in
addition to the P-values based on previous reports.25,26 The SNPs
that showed Q< 0.05 in the analysis were considered genome-wide
significant. To calculate Q-values in the third stage and for all
samples combined, Stratified False Discovery Rate (SFDR) soft-
ware was used (http://www.utstat.toronto.edu/sun/Software/
SFDR/index.html; accessed September 24, 2017).27
A log quantileequantile (QQ) P-value plot as a result of the
GWAS for the combined samples was subsequently drawn as
described previously.11 All of the plots were mostly concordant
with the expected line (y ¼ x), especially over the range of
0 < elog10 (P-value) < 5, indicating no apparent population
stratification of the samples used in the study (Supplementary
Fig. S1, S2).
The distributions of genotypes of the SNPs for PPLpre and
PPLpostePPLpre that were selected after the three-stage GWAS
were checked using the c2 test. The absence of significant deviation
from the theoretical distribution that is expected from
HardyeWeinberg equilibrium was confirmed for both phenotypes
(Supplementary Tables S1, S2). For the statistical analyses, SPSS 19
software (International Business Machines, Armonk, NY, USA) was
used. The criterion for significance was set at P < 0.05.
3. Results
We first explored the association between genetic variations
and pain sensitivity in a total of 353 healthy subjects who were
scheduled to undergo SSRO for mandibular prognathism that
involved the administration of opioid analgesics.11 Consequently,
five,11, and five SNPswere selected as the top candidates for PPLpre
in the additive, dominant, and recessive models for each minor
allele, respectively, after the final stage (Tables 1e3). Additionally,
six, seven, and six SNPs were selected as the top candidates for
PPLpostePPLpre in the additive, dominant, and recessive models
for eachminor allele, respectively, after the final stage (Tables 4e6).
The rs13093031 and rs12633508 SNPs that mapped to 3p11.1
showed significant associations with PPLpostePPLpre after the
final stage in the additive model (combined b ¼ 1.096, nominal
P ¼ 2.57  107 for the rs13093031 SNP; combined b ¼ 1.092,
nominal P ¼ 2.93  107 for the rs12633508 SNP) and recessive
model (combined b ¼ 2.239, nominal P ¼ 1.06  107 for the
rs13093031 SNP; combined b¼2.240, nominal P¼ 1.10 107 for
the rs12633508 SNP; Tables 4 and 6). The rs6961071 SNP that
mapped to 7q36.3 showed a significant association with
PPLpostePPLpre for all samples combined in the recessive model
(combined b ¼ 1.115, nominal P ¼ 2.74  107; Table 6). The
rs13093031, rs12633508, and rs6961071 SNPs showed no signifi-
cant associations with PPLpre after the final stage in the additive
model (combined b¼0.004, nominal P¼ 0.96 for the rs13093031
SNP; combined b ¼ 0.004, nominal P ¼ 0.97 for the rs12633508
SNP; combined b ¼ 0.032, nominal P ¼ 0.52 for the rs6961071
SNP), dominant model (combined b ¼ 0.058, nominal P ¼ 0.42 for
the rs13093031 SNP; combined b ¼ 0.062, nominal P ¼ 0.39 for the
rs12633508 SNP; combined b ¼ 0.021, nominal P ¼ 0.78 for the
rs6961071 SNP), and recessive model (combined b ¼ 0.031,
nominal P ¼ 0.86 for the rs13093031 SNP; combined b ¼ 0.032,
nominal P ¼ 0.85 for the rs12633508 SNP; combined b ¼ 0.098,
nominal P ¼ 0.27 for the rs6961071).
In the PPLpre groups, no SNPs were identified as genome-wide
significant. The observed P-values of 295,036 SNPs in each model
for PPLpre and PPLpostePPLpre, calculated as elog10 (P-value),
deviated from the expected values from the null hypothesis of a
uniform distribution in the QQ plot for the entire sample
(Supplementary Fig. S1, S2). The rs13093031 and rs12633508 SNPs
were located near the LOC728432 gene, which encodes interactor of
little elongation complex ELL subunit 2 pseudogene 2 (ICE2P2). Two
alleles of the LOC728432 gene SNPs (rs13093031 and rs12633508)
represented almost one absolute LD block near the LOC728432 gene
region (Fig. 1). The rs6961071 was located near the tcag7.1213 gene,
which is synonymous with LOC393076 and is a previously anno-
tated uncharacterized gene.
The PPLpostePPLpre values in subjects with the A/A, A/G, and G/
G genotypes of the rs13093031 SNP, reflecting the analgesic effects
of fentanyl, were 24.45 ± 2.088 s, 32.09 ± 3.767 s, and
0.400 ± 2.048 s (mean ± standard error of the mean [SEM]),
respectively (Fig. 2A). The PPLpostePPLpre values in subjects with
the A/A, A/G, and G/G genotypes of the rs6961071 SNP, were
27.79 ± 3.472 s, 31.04 ± 2.755 s, and 9.205 ± 1.734 s (mean ± SEM),
respectively (Fig. 2B).
Table 1
Top candidate SNPs for PPLpre selected from 3-stage GWAS (additive model).
Rank SNP CHR Position 1st stage 2nd stage Final stage Combined Related gene
b P b P b P Q b P Q0
1 rs1151357 12 130059982 0.48 0.0084 1.135 0.0001 0.2467 0.0490 0.9052 0.4114 0.0000159 0.2604 GPR133
2 rs2412504 15 38345356 0.4865 0.0026 0.2428 0.0357 0.3427 0.0352 0.9052 0.3448 0.0000318 0.409 PAK6
3 rs1195906 12 130071019 0.4567 0.0123 0.5787 0.0067 0.2307 0.0495 0.9052 0.3624 0.0000454 0.4563 GPR133
4 rs3827040 20 43948966 0.3611 0.0489 0.2833 0.0264 0.4302 0.0079 0.5067 0.3466 0.0001002 0.5593 C20orf165
5 rs12050748 15 24892817 0.2118 0.0419 0.1937 0.0258 0.1658 0.0290 0.9052 0.1869 0.0002206 0.7891 GABRA5
CHR, chromosome number; Position, chromosomal position (bp); Q, Q values for FDR correction in the third stage; Q0 , Q values for FDR correction for combined all samples;
Related gene, the nearest gene from the SNP site.
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Table 2
Top candidate SNPs for PPLpre selected from 3-stage GWAS (dominant model).
Rank SNP CHR Position 1st stage 2nd stage Final stage Combined Related gene
b P b P b P Q b P Q0
1 rs7874530 9 83645492 0.4046 0.0093 0.304 0.0140 0.4937 0.0002 0.0724 0.396 0.00000057 0.0917 FLJ43950
2 rs2031757 9 83641664 0.3589 0.0147 0.41 0.0012 0.3851 0.0030 0.3101 0.3849 0.000000679 0.0917 FLJ43950
3 rs679090 13 76445792 0.3338 0.0115 0.3643 0.0034 0.3468 0.0047 0.3697 0.3422 0.00000211 0.19 LOC390413
4 rs2194734 2 162034445 1.981 0.0054 0.8905 0.0031 0.7257 0.0116 0.4047 0.9269 0.00000708 0.248 TBR1
5 rs6432689 2 162088006 1.981 0.0054 0.8905 0.0031 0.7257 0.0116 0.4047 0.9269 0.00000708 0.248 KRT18P46
6 rs10182681 2 162112698 1.981 0.0054 0.8905 0.0031 0.7257 0.0116 0.4047 0.9269 0.00000708 0.248 KRT18P46
7 rs768835 2 162005765 1.981 0.0054 0.8808 0.0035 0.7257 0.0116 0.4047 0.9236 0.00000772 0.248 TBR1
8 rs6949736 7 48330883 0.2817 0.0432 0.3025 0.0155 0.4025 0.0008 0.1212 0.3247 0.0000101 0.248 ABCA13
9 rs9846242 3 9543136 0.4359 0.0195 0.4631 0.0143 0.4614 0.0162 0.5077 0.4528 0.0000291 0.5614 LHFPL4
10 rs2831306 21 28279043 0.2727 0.0393 0.2623 0.0184 0.2538 0.0320 0.7006 0.2648 0.0001382 0.6796 C21orf94
11 rs17394484 10 6776927 0.2824 0.0382 0.2303 0.0441 0.2615 0.0401 0.7016 0.262 0.0002936 0.801 LOC439949
CHR, chromosome number; Position, chromosomal position (bp); Q, Q values for FDR correction in the third stage; Q0 , Q values for FDR correction for combined all samples;
Related gene, the nearest gene from the SNP site.
Table 3
Top candidate SNPs for PPLpre selected from 3-stage GWAS (recessive model).
Rank SNP CHR Position 1st stage 2nd stage Final stage Combined Related gene
b P b P b P Q b P Q0
1 rs2412504 15 38345356 1.024 0.00148 0.5567 0.01655 0.6634 0.03905 0.9286 0.7223 0.0000116 0.2143 PAK6
2 rs1151357 12 130059982 0.9236 0.01061 2.281 0.0001001 0.5255 0.03274 0.9286 0.8208 0.0000143 0.2147 GPR133
3 rs1195924 12 130064055 0.8062 0.01311 1.159 0.006174 0.5162 0.02548 0.9286 0.711 0.0000291 0.3407 GPR133
4 rs1195906 12 130071019 0.8587 0.01774 1.159 0.006174 0.5162 0.02548 0.9286 0.7211 0.0000412 0.3665 GPR133
5 rs1381324 14 24279038 0.846 0.04286 0.8691 0.01255 0.4535 0.03852 0.9286 0.6325 0.0002076 0.7487 STXBP6
CHR, chromosome number; Position, chromosomal position (bp); Q, Q values for FDR correction in the third stage; Q0 , Q values for FDR correction for combined all samples;
Related gene, the nearest gene from the SNP site.
Table 4
Top candidate SNPs for PPLpost-PPLpre selected from 3-stage GWAS (additive model).
Rank SNP CHR Position 1st stage 2nd stage Final stage Combined Related gene
b P b P b P Q b P Q0
1 rs13093031 3 88941731 0.9449 0.0074 0.8982 0.0099 1.562 0.0002 0.0262a 1.096 0.000000257 0.0361a LOC728432
2 rs12633508 3 88897825 0.9454 0.0077 0.8852 0.0108 1.562 0.0002 0.0262a 1.092 0.000000293 0.0361a LOC728432
3 rs6715117 2 166729443 0.9669 0.0494 0.7182 0.0167 0.7146 0.0305 0.9569 0.7456 0.0002488 0.447 SCN9A
4 rs440869 14 76761405 1.677 0.0466 1.183 0.0279 1.758 0.0356 0.9569 1.438 0.0003945 0.5103 TMEM63C
5 rs10511452 9 3663041 0.6998 0.0151 0.4089 0.0460 0.472 0.0437 0.9569 0.4736 0.0005042 0.5103 RFX3
6 rs4738858 8 62126253 1.027 0.0357 0.5561 0.0384 0.5583 0.0499 0.9569 0.5674 0.001728 0.6191 LOC442389
CHR, chromosome number; Position, chromosomal position (bp); Q, Q values for FDR correction in the third stage; Q0 , Q values for FDR correction for combined all samples;
Related gene, the nearest gene from the SNP site.
a Significant after FDR correction (Q < 0.05 or Q' < 0.05).
Table 5
Top candidate SNPs for PPLpost-PPLpre selected from 3-stage GWAS (dominant model).
Rank SNP CHR Position 1st stage 2nd stage Final stage Combined Related gene
b P b P b P Q b P Q0
1 rs10486603 7 28994918 5.159 0.0018 3.625 0.0007 2.409 0.0131 0.5751 3.228 0.000000981 0.2628 CPVL
2 rs4413160 2 241243535 0.7639 0.0204 0.8102 0.0069 1.035 0.0015 0.2015 0.8677 0.00000235 0.3147 AQP12B
3 rs2060190 2 241242674 0.7445 0.0273 0.8466 0.0065 1.037 0.0023 0.2015 0.8741 0.00000412 0.3678 AQP12B
4 rs4149316 9 106621128 0.9114 0.0045 0.646 0.0211 0.66 0.0418 0.8901 0.7309 0.0000412 0.7882 ABCA1
5 rs2041570 7 31165792 0.6983 0.0221 0.5907 0.0366 0.6472 0.0366 0.8901 0.6558 0.0001386 0.8734 ADCYAP1R1
6 rs2678822 8 96131777 0.6141 0.0460 0.6922 0.0141 0.6267 0.0449 0.8901 0.645 0.0001963 0.8758 C8orf38
7 rs7250773 19 56998359 0.7744 0.0171 0.754 0.0253 0.6829 0.0459 0.8901 0.7019 0.0002516 0.8758 FPRL2
CHR, chromosome number; Position, chromosomal position (bp); Q, Q values for FDR correction in the third stage; Q0 , Q values for FDR correction for combined all samples;
Related gene, the nearest gene from the SNP site.
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4. Discussion
Analgesic effects can be evaluated as differences in the severity
of pain in standardized pain tests before and after analgesic
administration.17 We and other groups have reported several SNPs
that are associated with the sensitivity to opioids, such as
fentanyl.17e19,28,29 To our knowledge, no studies have explored as-
sociations between genetic polymorphisms and analgesic effects in
a GWAS. We conducted a GWAS, and three candidate SNPs
(rs13093031, rs12633508, and rs6961071) were selected. Subjects
with the G/G genotype of the rs13093031 and rs6961071 SNPs
presented lower analgesic sensitivity to fentanyl. These SNPs have
not been previously shown to be associated with opioid sensitivity,
thus demonstrating the novelty of our findings.
Two SNPs (rs13093031 and rs12633508) showed significant
associations with PPLpostePPLpre and were in strong LD with
each other. These two SNPs are located in the flanking region
near the 50 untranslated region of a pseudogene, ICE2P2.
Although no pseudogene has been previously reported to be
associated with opioid sensitivity, our findings suggest the pos-
sibility that the ICE2P2 pseudogene is associated with opioid
sensitivity by interfering with endo-siRNAs (esiRNAs) that
regulate particular genes. Pseudogenes may function as gene
regulators through the generation of esiRNAs.30 Future studies
Table 6
Top candidate SNPs for PPLpost-PPLpre selected from 3-stage GWAS (recessive model).
Rank SNP CHR Position 1st stage 2nd stage Final stage Combined Related gene
b P b P b P Q b P Q0
1 rs13093031 3 88941731 1.834 0.0083 1.882 0.0062 3.232 0.000095 0.0151a 2.239 0.000000106 0.0132a LOC728432
2 rs12633508 3 88897825 1.834 0.0086 1.882 0.0062 3.232 0.000095 0.0151a 2.24 0.00000011 0.0132a LOC728432
3 rs6961071 7 155667462 1.481 0.0001 0.7394 0.0362 1.078 0.00943 0.7497 1.115 0.000000274 0.0219a tcag7.1213
4 rs960434 7 31259425 0.9735 0.0169 0.9586 0.0263 1.164 0.009007 0.7497 1.051 0.0000186 0.2628 NEUROD6
5 rs6597458 7 154545784 0.8264 0.0444 0.8583 0.0131 0.7209 0.04573 0.8536 0.8114 0.0001424 0.3917 LOC644697
6 rs440869 14 76761405 3.353 0.0454 2.498 0.0206 3.592 0.03171 0.8536 2.944 0.0002854 0.4577 TMEM63C
CHR, chromosome number; Position, chromosomal position (bp); Q, Q values for FDR correction in the third stage; Q0 , Q values for FDR correction for combined all samples;
Related gene, the nearest gene from the SNP site.
a Significant after FDR correction (Q < 0.05 or Q' < 0.05).
Fig. 1. Linkage disequilibrium plot for the LOC728432 gene region. Numbers in the diamonds represent percentages of r2 values for all SNP pairs and were calculated from the
genotyped data for the orthognathic surgery samples. Blank squares represent r2 ¼ 100%. The rs13093031 SNP showed almost absolute linkage disequilibrium with the rs12633508
SNP, indicating similar results of association analyses obtained for these SNPs.
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should investigate whether the ICE2P2 pseudogene affects indi-
vidual differences in opioid sensitivity.
The present multistage GWAS identified rs6961071 as a potent
SNP that is associated with PPLpost-PPLpre. The rs6961071 SNP is
in the intron region of the tcag7.1213 gene, based on the annota-
tion file that was supplied by the BeadChip manufacturer. The
tcag7.1213 gene, also called LOC393076, is not currently annotated
in the National Center for Biotechnology Information database
(http://hapmap.ncbi.nlm.nih.gov/index.html.ja; September 24,
2017). No study has reported the influence of the rs6961071 SNP on
these gene functions. However, some reports suggest that the
intron region can affect gene function and expression.31 Our results
suggest the possibility that the rs6961071 SNP in the intron region
may influence opioid sensitivity.
We investigated PPLpostePPLpre and found a range of dif-
ferences in analgesic sensitivity. A total of 26 subjects had
negative PPLpostePPLpre values (12, five, and nine subjects in
the first-, second-, and final-stage analyses, respectively), sug-
gesting that these participants may have experienced opioid-
induced hyperalgesia.
In our previous report,11 several SNPs were associated with the
sensitivity to opioid analgesics for postoperative pain in subjects
who underwent SSRO, although the associations between most of
these SNPs and PPLpostePPLpre were not even nominally signifi-
cant (P 0.05; data not shown). In the present study, we focused on
thermal stimulation and identified different SNPs that may be
associated with the sensitivity to opioid analgesics in the same
cohort, although the associations between these SNPs and post-
operative analgesia were not even nominally significant (P  0.05;
data not shown). Various factors, including differences in the types
and degrees of pain and amount of fentanyl, may have resulted in
different candidate SNPs that were identified in the present and
previous studies.
Higher pain sensitivity can result from the long-term use of
opioid analgesics. Regular users of opioids are more sensitive to
pain than regular users of non-opioid analgesics.32 The United
States and Canada have a growing population of long-term opioid
users for non-cancer pain.33,34 Consequently, opioid misuse and
addiction are ongoing and rapidly evolving public health issues.35
In contrast, in Japan, few people use opioid analgesics over the
long-term. In the present study, we chose 355 healthy subjects who
did not have chronic pain and did not generally use analgesics.
Thus, our findings of several genome-wide significantly associated
SNPs were not confounded by possible changes in opioid sensitivity
in long-term opioid users.
In conclusion, based on our results, analgesic sensitivity may be
predicted by the identification of genotypes of genetic poly-
morphisms, which may ultimately lead to improvements in the
personalized treatment of pain. The present multistage GWAS
found that the rs13093031, rs12633508, and rs6961071 SNPs were
associated with the analgesic effects of opioids. Two polymorphic
loci (rs13093031 and rs12633508) were in strong LD. These SNPs
are located near the ICE2P2 pseudogene, whereas the rs6961071
SNP is located in the tcag7.1213 gene region. The functions of these
genes remain to be fully characterized.
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